AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical Trials on Treatment of Periodontitis

NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has signed a cannabinoid product supply agreement with Impression Healthcare Limited (“Impression”) for the supply of the Company’s toothpaste and mouthwash containing cannabidiol (CBD) for its clinical trial for the treatment of periodontitis.

The supply agreement is in preparation for a clinical trial testing the effectiveness of CBD in treating periodontitis, to be performed at Swinburne University of Technology in Melbourne, Australia.

In accordance with the agreement, AXIM will supply the first batch of its patented toothpaste and mouthwash products containing CBD, along with associated placebo units for Impression to perform a randomized control clinical trial.

“With the prevalence of periodontitis worldwide, AXIM recognizes the need to provide consumers with an effective and

... read more at: https://globenewswire.com/news-release/2019/06/03/1863300/0/en/AXIM-Biotechnologies-Inc-Signs-Cannabinoid-Product-Supply-Agreement-with-Healthcare-Company-for-Clinical-Trials-on-Treatment-of-Periodontitis.html